More Articles

DIA Biosimilars Conference 2020 Conferences | Posted 18/09/2020

DIA Biosimilars Conference 2020 6‒7 October 2020 Virtual ConferenceUSA

Budget savings from biosimilar infliximab in the UK, France, Japan and Korea Biosimilars/Research | Posted 11/09/2020

Biological medicines are attracting attention from policymakers and health insurers across countries due to their increased financial burden. The potential for biosimilars’ cost savings can be infl...

Samsung Bioepis launches Ontruzant in Brazil Biosimilars/News | Posted 11/09/2020

South Korean biotechnology company Samsung Bioepis has announced the launch of their trastuzumab biosimilar Ontruzant in Brazil. The product was approved by the Brazilian health agency in May 2019.

Duopharma to establish Malaysia’s first commercial biosimilar facility Biosimilars/General | Posted 11/09/2020

Malaysia-based manufacturer Duopharma Biotech aims to establish Malaysia’s first commercial biosimilar production facility. The company is also working to achieve halal certification for its erythr...

Cadila Pharmaceuticals launches two similar biologics in India Biosimilars/News | Posted 11/09/2020

Indian generics maker Cadila Pharmaceuticals Ltd (Cadila) has launched two new similar biologics in the country: Bevaro (bevacizumab) and Ritucad (rituximab).

Celltrion’s biosimilars effective against gastric cancer and B-cell lymphoma Biosimilars/Research | Posted 11/09/2020

Recent clinical trial results confirm that Celltrion’s biosimilars Herzuma (trastuzumab) and Truxima (rituximab) are effective in the treatment of gastric cancer and B-cell lymphoma, respectively.

Mylan launches first generic of Tecfidera in the US Generics/News | Posted 11/09/2020

On 19 August 2020, Mylan announced the launch of the first US Food and Drug Administration (FDA) approved generic of Biogen's multiple sclerosis (MS) treatment Tecfidera (dimethyl fumarate).

Evaluating reasons for US low generics substitution rates Generics/Research | Posted 11/09/2020

The uptake of generic drug products in the US has not met expectations despite their widespread availability and relatively low cost. A team of researchers based at Johns Hopkins University in the...